How could the CDMO sector's growth affect MSCI's index ratings and inclusion decisions?
MSCI's index decisions may be influenced by CDMO sector's strong growth The CDMO sector is currently experiencing strong growth, driven by higher commercial demand and a revival in biotech funding. This trend is reflected in companies like Laurus Labs, which saw a massive 75 percent jump in CDMO revenues last quarter and is heavily investing in new manufacturing capacity. Since MSCI formally included Laurus Labs in its global and India standard indices, resulting in an upgrade status, the sustained positive momentum and increased investment in the sector could lead MSCI to adjust its ratings or inclusion criteria for other companies within the CRDMO space.
- Effect
- Mild positive
- How direct
- Brind's reasoning
- When
- Within months
- The story
- No new developments lately
How it reaches MSCI
-
Contract research, development, and manufacturing organizations (CRDMOs) are reporting upbeat business prospects, despite revenue softness at pharmaceutical companies in the US. Laurus Labs and Piramal Pharma reported strong September quarter results, with revenues increasing by 33 percent and 28 percent, respectively. Piramal Pharma’s growth was led by its CDMO business, which added 22 new customers in the first half of FY27.
The full event1independent outlet -
Laurus Labs has a known connection with MSCI, having been formally included in its global and India standard indices, resulting in an upgrade status. The sustained positive momentum and heavy investment in the CDMO sector, as demonstrated by Laurus Labs, provides the underlying financial strength that MSCI uses to determine index inclusion and rating status.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
American financial service provider
Everything about MSCI
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Laurus Labs saw a massive 75 percent jump in CDMO revenues last quarter.moneycontrol.com
- Laurus Labs incurred as much as 20 percent of its revenues as capex in H1 FY27.moneycontrol.com
- Piramal Pharma added 22 new customers in its CDMO business in H1 FY27.moneycontrol.com
- MSCI formally included Laurus Labs in its global and India standard indices, resulting in an upgrade status.moneycontrol.com
Why it matters
For MSCI, the strength of the CDMO sector validates the growth potential of the companies it tracks. Since MSCI's core business involves assessing and classifying companies based on financial health and growth, a sector-wide boom driven by high commercial demand and heavy investment directly impacts the data and metrics used in its index construction and rating methodologies.
This trend is not isolated; other CRDMOs are also ramping up investments in new facilities and capabilities to capture business opportunities. The sector's ability to climb the value chain with differentiated offerings, such as antibody-drug conjugate (ADCs) and peptides, is key to delivering long-term returns, which is a factor MSCI considers when evaluating companies.
What we don't know yet
- Will MSCI adjust its criteria to specifically reward companies in the high-growth CDMO segment?
- How will the continued investment in difficult-to-develop capabilities affect the long-term valuation of these companies?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- moneycontrol.comFriday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.